title: Risk factors for rate of decline in FEV1 in adults with cystic fibrosis.
abstract: BACKGROUND
  Previously we assessed risk factors for FEV(1) decline in children and adolescents using the Epidemiologic Study of Cystic Fibrosis (J Pediatr 2007;151:134-139); the current study assessed risk factors in adults.
  
  
  METHODS
  Risk factors for FEV(1) decline over 3-5.5 years for ages 18-24 and ≥25 years were assessed using mixed-model regression.
  
  
  RESULTS
  Mean rates of FEV(1) decline (% predicted/year) were -1.92 for ages 18-24y (n=2793) and -1.45 for ages ≥25y (n=1368). For the 18-24y group, B. cepacia, pancreatic enzyme use, multidrug-resistant P. aeruginosa, cough, mucoid P. aeruginosa, and female sex predicted greater decline; low baseline FEV(1) and sinusitis predicted less decline. For the ≥25y group, only pancreatic enzyme use predicted greater decline; low baseline FEV(1) and sinusitis predicted less decline.
  
  
  CONCLUSIONS
  Risk factors for FEV(1) decline in adults <25 years are similar to those previously identified in children and adolescents; older adults had few statistically significant risk factors.
authors.affiliation: Case Western Reserve University School of Medicine and Rainbow Babies and Children's Hospital, Cleveland, OH 44106, USA. Michael.Konstan@UHhospitals.org
authors.forename: Michael W
authors.initials: MW
authors.lastname: Konstan
authors.forename: Jeffrey S
authors.initials: JS
authors.lastname: Wagener
authors.forename: Donald R
authors.initials: DR
authors.lastname: Vandevanter
authors.forename: David J
authors.initials: DJ
authors.lastname: Pasta
authors.forename: Ashley
authors.initials: A
authors.lastname: Yegin
authors.forename: Lawrence
authors.initials: L
authors.lastname: Rasouliyan
authors.forename: Wayne J
authors.initials: WJ
authors.lastname: Morgan
mesh_terms: D000328:Adult; D000367:Age Factors; D003550:Cystic Fibrosis / Q000150:complications / Q000175:diagnosis / Q000453:epidemiology* / Q000503:physiopathology* / Q000628:therapy; D018450:Disease Progression; D056947:Enzyme Replacement Therapy / Q000706:statistics & numerical data; D005260:Female; D006801:Humans; D008297:Male; D009752:Nutritional Status; D010179:Pancreas / Q000201:enzymology; D011552:Pseudomonas Infections / Q000503:physiopathology*; D011550:Pseudomonas aeruginosa / Q000302:isolation & purification*; D012044:Regression Analysis; D012129:Respiratory Function Tests / Q000379:methods / Q000706:statistics & numerical data; D012137:Respiratory System / Q000503:physiopathology*; D012141:Respiratory Tract Infections / Q000382:microbiology / Q000503:physiopathology; D012307:Risk Factors; D012737:Sex Factors